Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Date:3/9/2008

SEATTLE, March 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) management will present at the 7th Annual WBBA Invest Northwest Conference on Tuesday, March 18th at 9:00 AM in the Bay Auditorium of the Bell Harbor Conference Center.

The presentation will also be webcast live with slides, and available for replay after the presentation. The webcast can be accessed at http://www.cticseattle.com.

WBBA Invest Northwest Conference

CTI Presentation: Tuesday, March 18, 2008

9:00 AM PDT/12:00 PM EDT/5:00 PM CET

Bay Auditorium, Bell Harbor Conference Center

Audio webcast with slides at http://www.cticseattle.com

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.272.4345

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
2. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
3. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
6. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
7. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
8. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
9. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
10. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
11. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...TA and LACHEN, Switzerland, Dec. 4 ...ounced that Dennis D. Curtin has been,selected to... States. Curtin,had been Octapharma,s U.S. legal ...t of Life Therapeutics, Inc. , The largest ...pharma,recently acquired Life Therapeutics, the A...
(Date:12/4/2008)...ORK, Dec. 4 NeoStem, Inc...he pre-disease collection,processing and long-te...need,today announced that it has reached a major...opening of the first ever collection center for co...c for future medical need in New York,City and ha...
(Date:12/4/2008)...N, December 4 Azur Pharma Limited ... a definitive agreement with BioSante,Pharmaceuti... U.S. rights to,Elestrin(TM). Elestrin is a fast ...cated for the treatment of moderate to severe vaso...n was approved by the U.S. Food and Drug,Administ...
(Date:12/4/2008)...M, N.C., Dec. 4 Parion Sciences, I...nces (Nasdaq: GILD ), has initiated a Phase I,c...valuate the safety and,tolerability of the invest...e,airway hydration for the treatment of pulmonary...n epithelial sodium channel (ENaC) blocker discove...
Breaking Biology Technology:Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 3
...be impressive enough if the robotics engineering t... Louis Park, Minn., had won a national championshi...re impressive that their competitors were seasoned...mp, students from the Minneapolis-area school comp...e 2005 U.S. Open RoboCup. Using robots to navigate...
...ays, Promega Corp . has given Northwestern Mutua...Quiet to those outside the life-science realm, tha... Madison walls, it,s anything but silent, as a con...hat innovation has produced about 200 patents and ...ew product innovations since 2002. , ,That pace ha...
... , a Madison-based stock image distributor, has be...g to a report in pdn online . , ,Terms of the d...dly is part of a business strategy for Getty Image... of customers. , ,PunchStock employs 60 people an... Kingdom. It offers royalty-free images and distri...
...0th in a series of articles on developing start-up...ors. , , Madison, Wis. - In Step 9 we discusse...me we focus specifically on the federal laws. , ,...bject to both state and federal securities laws an...ies laws of those states from and into which a bus...
Other Biology Technology:Silver linings in the cloud: America's dearth of STEM students 2Silver linings in the cloud: America's dearth of STEM students 3Silver linings in the cloud: America's dearth of STEM students 4Promega Corporation: Wisconsin's quiet innovator 2Promega Corporation: Wisconsin's quiet innovator 3Promega Corporation: Wisconsin's quiet innovator 4Promega Corporation: Wisconsin's quiet innovator 5Early Stage 10: The nuances of federal laws 2Early Stage 10: The nuances of federal laws 3Early Stage 10: The nuances of federal laws 4Early Stage 10: The nuances of federal laws 5
(Date:12/3/2008)...Richard H. Jones, deputy executive director of the...rld Energy Outlook 2008" Dec. 9 at Rice University...ll address such questions as: Is the world facing ...nvestment? What type of post-Kyoto policy framewor...ation levels, and what impact might such a policy ...
(Date:12/3/2008)...GAINESVILLE, Fla. The wild pea pod is big and hea...hade of its parent plant. , And yet, like a grou...den, it manages if it has a reasonable chance of ...ing at the world,s largest experimental landscape ... woods or other natural areas have discovered the...
(Date:12/3/2008)...Using a harmless virus to insert a corrective gene...ildren,s Research Hospital have alleviated sickle ...archers found that the treated mice showed essenti...scientists caution that applying the gene therapy ..., they believe that the new therapy will become an...
(Date:12/3/2008)...A multi-institution team of investigators led by r...niversity of Southern California (USC) has receive...tes of Mental Health (NIMH) for a groundbreaking e...ousands of patients in order to study the genetic ... The USC Center for Genomic Psychiatry and Massach...
Breaking Biology News(10 mins):'World Energy Outlook' to be presented at Rice University Dec. 9 2Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 3Dr Dan L Fortenbacher O D FCOVD Becomes 29th President of College of Optometrists in Vision Development 28COVD 29 3B Unveils 7 Part Development 5415 1Dr Dan L Fortenbacher O D FCOVD Becomes 29th President of College of Optometrists in Vision Development 28COVD 29 3B Unveils 7 Part Development 5415 2Dr Dan L Fortenbacher O D FCOVD Becomes 29th President of College of Optometrists in Vision Development 28COVD 29 3B Unveils 7 Part Development 5415 3AUDIO from Medialink and P 26G 3A New Tools for Promoting Good Mouth Health 5413 1Lung Cancer Alliance Launches Lung Cancer Awareness Month With Third Annual Report Card on Lung Cancer 5411 1Lung Cancer Alliance Launches Lung Cancer Awareness Month With Third Annual Report Card on Lung Cancer 5411 2XTENT Announces Third Quarter 2007 Financial Results 5409 1XTENT Announces Third Quarter 2007 Financial Results 5409 2XTENT Announces Third Quarter 2007 Financial Results 5409 3XTENT Announces Third Quarter 2007 Financial Results 5409 4
...breathing a sigh of relief, as they no longer run ...ase-fighting substances. Scientists recently disco...h lives symbiotically inside the sea squirt, actua...hat may one day be used in cancer treatment. , Des...cessfully cultivate Prochloron in the laboratory o...
...ences Professor Daniel F. Eberl and his colleagues... leading to deafness in fruit flies that may shed ... "Myosin VIIA Defects, which Underlie the Usher 1B...a," is scheduled for publication in the May 10 iss...eir recent work -- showing that loss of function i...
...nd in blood, can be fused with large, protein-base...tor (G-CSF) to create a new oral compound that is ...ointestinal (GI) tract and then able to cross over...rding to research from the University of Southern ...ay allow for oral administration of drugs that pre...
...bugs. The rates of drug-resistant bacteria infecti...ave been increasing steadily in recent years, acco...linical Infectious Diseases, now available online....problem due in part to inappropriate prescribing a...uperbugs" can infect people and cause health probl...
Other Biology News:UI researcher studies deafness in fruit flies, humans 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 2Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs 3Two studies document rise of superbugs in the environment 2Two studies document rise of superbugs in the environment 3
...ne TC-512 is the only Gradient thermal cycler whic...touch of a screen. ,Wide linear gradient - The m...amazing range of,30C. Protocols can be optimised i...ene Gradient incorporates a large, 115 x 90mm, tou...
...dom EVO Clinical is Tecans open platform for clini... to enhance quality, safety and performance in the...afety is provided by flexible barcode reading and ...ention that the system complies with the IVD-Direc...
Request Info
Features Provides a buffered anti-freeze environment for enzyme conjugated antibodies and proteins , Maintains a liquid, low viscosity solution at -20C , No aliquoting of conjugate is necessary an
Biology Products: